142 related articles for article (PubMed ID: 7687516)
1. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
Zagars GK; Pollack A
Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
Zagars GK; Pollack A
Radiother Oncol; 1997 Sep; 44(3):213-21. PubMed ID: 9380819
[TBL] [Abstract][Full Text] [Related]
3. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Pollack A; Zagars GK; Kavadi VS
Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
[TBL] [Abstract][Full Text] [Related]
7. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
Kavadi VS; Zagars GK; Pollack A
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
[TBL] [Abstract][Full Text] [Related]
8. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Pollack A; Zagars GK; el-Naggar AK; Terry NH
Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.
Zagars GK
Int J Radiat Oncol Biol Phys; 1992; 23(1):47-53. PubMed ID: 1374065
[TBL] [Abstract][Full Text] [Related]
10. Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma.
Hanlon AL; Moore DF; Hanks GE
Cancer; 1998 Jul; 83(1):130-4. PubMed ID: 9655302
[TBL] [Abstract][Full Text] [Related]
11. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer.
Schaefer U; Micke O; Willich N
Anticancer Res; 1999; 19(4A):2645-8. PubMed ID: 10470211
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.
Zagars GK; von Eschenbach AC
Cancer; 1993 Jul; 72(2):538-48. PubMed ID: 7686443
[TBL] [Abstract][Full Text] [Related]
14. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment.
Zagars GK; Pollack A
Radiother Oncol; 1994 Feb; 30(2):121-7. PubMed ID: 7514308
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
[TBL] [Abstract][Full Text] [Related]
17. Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate.
Geist RW
Urology; 1995 Jun; 45(6):1016-21. PubMed ID: 7539558
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
Zagars GK; Sherman NE; Babaian RJ
Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
[TBL] [Abstract][Full Text] [Related]
20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
